AR017440A1 - Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion - Google Patents

Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion

Info

Publication number
AR017440A1
AR017440A1 ARP980106565A ARP980106565A AR017440A1 AR 017440 A1 AR017440 A1 AR 017440A1 AR P980106565 A ARP980106565 A AR P980106565A AR P980106565 A ARP980106565 A AR P980106565A AR 017440 A1 AR017440 A1 AR 017440A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
phenyl
fpt inhibitor
antineoplastic agent
Prior art date
Application number
ARP980106565A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR017440(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR017440A1 publication Critical patent/AR017440A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980106565A 1997-12-22 1998-12-21 Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion AR017440A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
AR017440A1 true AR017440A1 (es) 2001-09-05

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980106565A AR017440A1 (es) 1997-12-22 1998-12-21 Uso de un inhibidor de fpt y de un agente antineoplasico en la preparacion de un medicamento para terapia de combinacion

Country Status (25)

Country Link
EP (1) EP1041985B1 (cg-RX-API-DMAC7.html)
JP (1) JP4502503B2 (cg-RX-API-DMAC7.html)
KR (1) KR100700907B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129431C (cg-RX-API-DMAC7.html)
AR (1) AR017440A1 (cg-RX-API-DMAC7.html)
AT (1) ATE317697T1 (cg-RX-API-DMAC7.html)
AU (1) AU756762B2 (cg-RX-API-DMAC7.html)
BR (1) BR9814419A (cg-RX-API-DMAC7.html)
CA (1) CA2315693C (cg-RX-API-DMAC7.html)
CL (1) CL2007001889A1 (cg-RX-API-DMAC7.html)
CO (1) CO5080764A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298511B6 (cg-RX-API-DMAC7.html)
DE (1) DE69833509T2 (cg-RX-API-DMAC7.html)
DK (1) DK1041985T3 (cg-RX-API-DMAC7.html)
ES (1) ES2255196T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0102473A3 (cg-RX-API-DMAC7.html)
IL (1) IL136462A0 (cg-RX-API-DMAC7.html)
MY (1) MY137303A (cg-RX-API-DMAC7.html)
NO (1) NO326832B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504928A (cg-RX-API-DMAC7.html)
PE (1) PE20000042A1 (cg-RX-API-DMAC7.html)
PT (1) PT1041985E (cg-RX-API-DMAC7.html)
SK (1) SK285584B6 (cg-RX-API-DMAC7.html)
TW (1) TW581763B (cg-RX-API-DMAC7.html)
WO (1) WO1999032114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001242434A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
WO2001064217A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
WO1997036583A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania Sensitization of cells to radiation and chemotherapy
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
AU3215197A (en) * 1996-05-30 1998-01-05 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
DE69837754T2 (de) * 1997-02-18 2008-02-07 Canji, Inc., San Diego Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Also Published As

Publication number Publication date
HUP0102473A2 (hu) 2002-01-28
HUP0102473A3 (en) 2003-07-28
DE69833509D1 (de) 2006-04-20
ES2255196T3 (es) 2006-06-16
CL2007001889A1 (es) 2008-01-11
CA2315693C (en) 2010-11-30
SK285584B6 (sk) 2007-04-05
EP1041985B1 (en) 2006-02-15
CN1284875A (zh) 2001-02-21
CO5080764A1 (es) 2001-09-25
IL136462A0 (en) 2001-06-14
CN1129431C (zh) 2003-12-03
WO1999032114A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
AU756762B2 (en) 2003-01-23
SK8982000A3 (en) 2001-04-09
MY137303A (en) 2009-01-30
TW581763B (en) 2004-04-01
PT1041985E (pt) 2006-07-31
PE20000042A1 (es) 2000-02-17
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
KR100700907B1 (ko) 2007-03-29
NO20003229D0 (no) 2000-06-21
KR20010033452A (ko) 2001-04-25
NO326832B1 (no) 2009-02-23
JP4502503B2 (ja) 2010-07-14
DK1041985T3 (da) 2006-06-19
DE69833509T2 (de) 2006-10-26
NZ504928A (en) 2004-12-24
CZ298511B6 (cs) 2007-10-24
EP1041985A1 (en) 2000-10-11
NO20003229L (no) 2000-08-22
ATE317697T1 (de) 2006-03-15
AU1907299A (en) 1999-07-12
JP2001526224A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GEP20032896B (en) 4-Aminothiazole Derivatives, Containing Them Pharmaceutical Compositions Inhibiting Cyclin-Dependent Kinases and Methods for Treatment
FR2678938B1 (fr) Derives de pyrrolidine, leur preparation et les medicaments les contenant.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
GEP20063799B (en) Tropane derivatives useful in therapy
DK0776202T3 (da) Liposomalt indkapslet taxol, dets fremstilling af dets anvendelse
FI863652A0 (fi) 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning.
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
CO5080764A1 (es) Metodos para el tratamiento de enfermedades proliferativas
FI895520A0 (fi) Anti-aterosklerotiska diaryl foereningar.
DK0539479T3 (da) Heterocykliske forbindelser
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
ATE146361T1 (de) Therapeutische mittel für die behandlungder resistenz gegen arzneimittel bei krebs
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
IL141515A (en) Optically active pyridyl- 4h - 1, 2, 4 - oxadiazine derivative and its use in the treatment of vascular diseases and pharmaceutical composition comprising same
ITRM930286A0 (it) Composizione farmaceutica per somministrazione rettale nel trattamentodi cefaleo e relativo metodo di preparazione ed impiego.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
GEP20043225B (en) 1-Trifluoromethyl-4-Hydroxy-7- Piperidinyl-Aminomethylchroman Derivatives
ES2086526T3 (es) Aplicacion medicinal de m-csf.
YU29803A (sh) Kombinacija kamptotekina i derivata stilbena za lečenje raka
GEP20022613B (en) Compositions with Beneficial Organoleptic Properties and Their Solvates, Method for Their Production and Pharmaceutical Compound Containing the Same

Legal Events

Date Code Title Description
FB Suspension of granting procedure